DE3583799D1 - Feste zubereitung mit langsamer freisetzung. - Google Patents

Feste zubereitung mit langsamer freisetzung.

Info

Publication number
DE3583799D1
DE3583799D1 DE8585300215T DE3583799T DE3583799D1 DE 3583799 D1 DE3583799 D1 DE 3583799D1 DE 8585300215 T DE8585300215 T DE 8585300215T DE 3583799 T DE3583799 T DE 3583799T DE 3583799 D1 DE3583799 D1 DE 3583799D1
Authority
DE
Germany
Prior art keywords
slow release
solid preparation
active ingredient
compsn
alginate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585300215T
Other languages
English (en)
Inventor
Rodney Dr Horder
Michel Dr Banks
Thomas Herbert Hoadley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE3583799D1 publication Critical patent/DE3583799D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
DE8585300215T 1985-01-11 1985-01-11 Feste zubereitung mit langsamer freisetzung. Expired - Lifetime DE3583799D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19850300215 EP0188040B1 (de) 1985-01-11 1985-01-11 Feste Zubereitung mit langsamer Freisetzung

Publications (1)

Publication Number Publication Date
DE3583799D1 true DE3583799D1 (de) 1991-09-19

Family

ID=8194116

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585300215T Expired - Lifetime DE3583799D1 (de) 1985-01-11 1985-01-11 Feste zubereitung mit langsamer freisetzung.

Country Status (7)

Country Link
US (1) US4842866A (de)
EP (1) EP0188040B1 (de)
AT (1) ATE66143T1 (de)
CA (1) CA1273873A (de)
DE (1) DE3583799D1 (de)
ES (1) ES8705757A1 (de)
GR (1) GR860060B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188040B1 (de) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Feste Zubereitung mit langsamer Freisetzung
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
CA1302659C (en) * 1986-10-24 1992-06-09 Hans-Peter K. Gribi Dental impression material
EP0275336A1 (de) * 1987-01-20 1988-07-27 Knoll Ag Arzneimittelzubereitung mit protahierender Wirkung
US5064736A (en) * 1988-03-23 1991-11-12 Olin Corporation Electrostatic method for multicolor imaging from a single toner bath
DE4002281A1 (de) * 1990-01-26 1991-08-01 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit dem wirkstoff tulobuterol
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
FR2676364B1 (fr) * 1991-05-17 1993-09-10 Lafon Labor Composition pharmaceutique a base de derives d'aminobutanone.
US5368862A (en) * 1991-12-18 1994-11-29 Merck & Co., Inc. Sustained release tablets containing alginate
US5411746A (en) * 1993-02-24 1995-05-02 Warner-Jenkinson Company, Inc. Dye compositions and methods for film coating tablets and the like
US5670169A (en) * 1993-12-20 1997-09-23 E.R. Squibb & Sons, Inc. Wound hydrating gel with novel preservative system and low cytotoxicity
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
DE4443358A1 (de) * 1994-12-06 1996-06-13 Basf Ag Depot-Arzneimittel
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
SI20108B (en) * 1997-06-11 2001-12-31 Abbott Lab A controlled release formulation for poorly soluble basic drugs
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
BG65116B1 (bg) * 2000-01-06 2007-03-30 Abbott Laboratories Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
EP1313486A1 (de) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung des clarithromycins und eines clarithromycin-zwischenprodukt; clarithromycin wesentlich frei von oxime; und pharmazeutische zusammensetzung die sie enthalten
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
CA2465405A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
EP1648418A4 (de) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8246996B2 (en) 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
EP1765336A4 (de) 2004-06-25 2010-03-10 Univ Johns Hopkins Angiogenesehemmer
EP1771158A4 (de) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Tablette für pulsierte abgabe
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
CA2617150C (en) * 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
EP2324886A1 (de) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Neue deuterierte Analoga des Tadalafils
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
EP2586433A1 (de) * 2006-03-17 2013-05-01 Johns Hopkins University School of Medicine N-hydroxylsulfonamidderivate als neue physiologisch nützliche Nytroxyl-Spender
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8551995B2 (en) 2007-01-19 2013-10-08 Xcovery Holding Company, Llc Kinase inhibitor compounds
KR101813551B1 (ko) 2007-09-26 2018-01-02 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 n-히드록실술폰아미드 유도체
DK2234607T3 (da) * 2007-12-28 2011-11-21 Acraf Formulering med langsom frigivelse på basis af en forbindelse af glykogen og alginat
US8318705B2 (en) 2008-05-07 2012-11-27 Cardioxyl Pharmaceuticals, Inc. Nitroso compounds as nitroxyl donors and methods of use thereof
JP5670325B2 (ja) 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
MX2012006265A (es) 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
CN102753519B (zh) * 2009-12-07 2015-08-05 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物
US20110144067A1 (en) * 2009-12-07 2011-06-16 Toscano John P N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
US20120082720A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
US20120082719A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
CN103298806B (zh) 2010-10-08 2015-03-18 贝达药业股份有限公司 取代的哒嗪羧酰胺化合物
SG11201401587QA (en) 2011-10-17 2014-07-30 Univ Johns Hopkins Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
NZ748771A (en) 2013-01-18 2019-12-20 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
CN105377292A (zh) 2013-04-07 2016-03-02 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148983A1 (de) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylaminobarbitursäure-derivate als nitroxyldonatoren
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
RU2017126462A (ru) 2014-12-23 2019-01-24 Церекор, Инк. Соединения, композиции и способы
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
AU2016276783B2 (en) 2015-06-09 2020-07-02 Rexahn Pharmaceuticals, Inc. Fluorocyclopentenylcytosine uses and processes of preparation
KR101592144B1 (ko) 2015-06-19 2016-02-04 고려대학교 산학협력단 요오드 캡슐, 이의 제조방법 및 이를 포함하는 소금
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
EP3344250A2 (de) 2015-09-04 2018-07-11 Rexahn Pharmaceuticals, Inc. Chinoxalinyl-piperazinamid, verfahren zur verwendung
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
HUE058120T2 (hu) 2016-10-03 2022-07-28 Highlightll Pharmaceutical Hainan Co Ltd Új JAK1-szelektív inhibitorok és alkalmazásuk
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
RU2020136057A (ru) 2018-05-04 2022-05-04 Толлиз Лиганды tlr3, которые активируют как эпителиальные, так и миелоидные клетки
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020215037A1 (en) 2019-04-18 2020-10-22 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
KR20230029673A (ko) 2020-05-26 2023-03-03 디오니스 테라퓨틱스, 아이엔씨. 핵산 인공 미니-프로테옴 라이브러리
WO2021248093A1 (en) 2020-06-05 2021-12-09 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
JP2024501995A (ja) 2020-12-22 2024-01-17 メカニスティク・セラピューティクス・エルエルシー Egfr及び/又はpi3k阻害剤としての置換アミノベンジルヘテロアリール化合物
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR985218A (fr) * 1948-04-27 1951-07-16 Medical Alginates Ltd Perfectionnements aux procédé d'application des produits alginatés
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
DE2062715C3 (de) * 1970-12-19 1974-03-21 Efeka Friedrich & Kaufmann Arzneimittelfabrik, 3000 Hannover Verfahren zur Herstellung von oral applizierbaren Arzneimittelzubereitungen mit protrahierter Wirkstoffabgabe und Arzneimittelzubereitung
EP0188040B1 (de) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Feste Zubereitung mit langsamer Freisetzung
JP2971660B2 (ja) * 1991-03-29 1999-11-08 株式会社東芝 超電導磁石装置
JP3000771B2 (ja) * 1991-12-20 2000-01-17 株式会社日立製作所 磁気浮上式走行体とその走行安定方法

Also Published As

Publication number Publication date
GR860060B (en) 1986-05-12
US4842866A (en) 1989-06-27
EP0188040B1 (de) 1991-08-14
EP0188040A1 (de) 1986-07-23
ATE66143T1 (de) 1991-08-15
ES550807A0 (es) 1987-05-16
CA1273873A (en) 1990-09-11
ES8705757A1 (es) 1987-05-16

Similar Documents

Publication Publication Date Title
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
GR3004531T3 (de)
AU582920B2 (en) Continuous release pharmaceutical compositions
DE59003337D1 (de) Pressling mit retardierter Wirkstofffreisetzung.
ZA879173B (en) Therapeutic agents
AU7001487A (en) Difluorohalomethoxyphenyl derivative and miticide comprising said derivative as active ingredient
BR9809571A (pt) Composição medicinal e processo para produzì-la
ZA884622B (en) Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
SE8400723D0 (sv) Farmaceutisk komposition
HUT39957A (en) Insecticide and acaricide compositions and process for preparing the active ingredients
IL94103A0 (en) Water-containing formulations with phospholipids,their preparation and application
EP0294053A3 (en) Physiologically active agent for agricultural use
IT1229223B (it) Composizioni veterinarie sinergisticamente attive e procedimento per la loro preparazione.
EP0390849A4 (en) Methyl cellulose pharmaceutical composition
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
HUT53891A (en) Nematocide insecticide and acaricide comprising 5-substituted-3-arylisoxazole derivatives as active ingredient and process for producing the active ingredients
ZA907183B (en) 13-alkyl-23-imino and 13-halo-23-imino derivatives of ll-f28249 compounds and their use as endo-and ecto-parasiticidal insecticidal,acaricidal and nematocidal agents
IL85451A (en) 26, 27-mono- and 14,15:26,27-diepoxy g22-ll-f28249 derivatives and their pesticidal use
IL86720A0 (en) Emulsifying agent,its preparation and use
ES2055847T3 (es) Agente fijador de fosfato para administracion por via oral.
EP0190860A3 (de) 6-Chloro-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepin-N-oxyd und dieses enthaltende Arzneimittel
GB8921069D0 (en) Pharmaceutically active compound,preparation and use
DE3760174D1 (en) 2-substituted 4,4,7,7-tetramethyl-1,3-dioxacycloheptanes, their preparation and use as parfumes
MX17042A (es) (1) benzotiopirano (4,3-c)-pirazoles y procedimiento para su preparacion.
FI920222A0 (fi) Doseringsmedel innefattande en jonofor.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition